Mankind Pharma

Mankind Pharma Net Debt per Share

The Net Debt per Share of Mankind Pharma (MANKIND.NS) as of Nov 1, 2026 is 151.79 INR. In the previous year, Net Debt per Share was -78.70 INR — a change of -292.87% (higher).

Net Debt per Share

151.79INR

YoY

-292.87%

Last updated:

Net Debt per Share of Mankind Pharma is 2025 151.79 INR. Net Debt per Share of Mankind Pharma was 2024 -78.70 INR. It decreases by -292.87% higher compared to the previous year.

The Mankind Pharma Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2020
-23.03 INR
Jan 1, 2021
-41.78 INR
Jan 1, 2022
-9.59 INR
Jan 1, 2023
-32.90 INR
Jan 1, 2024
-78.70 INR
Jan 1, 2025
151.79 INR
The Mankind Pharma Net Debt per Share history
YEARNet Debt per ShareYoY
151.79INR-292.87%
-78.70INR+139.19%
-32.90INR+243.25%
-9.59INR-77.06%
-41.78INR+81.41%
-23.03INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mankind Pharma Stock analysis

What does Mankind Pharma do? Mankind Pharma Ltd develops, manufactures, and markets pharmaceutical formulations across therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, and respiratory treatments. The company's portfolio includes brands such as Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, and Monticop, targeting acute and chronic conditions. These products are sold to healthcare providers, hospitals, and pharmacies across India, serving patients in diverse medical needs. The firm generates revenue through the sale of prescription and over-the-counter pharmaceuticals, leveraging its extensive portfolio in multiple therapeutic segments. Mankind Pharma focuses on therapeutic areas like anti-diabetic, dermatology, gynecology, pain/analgesics, urology, ophthalmology, and antiviral treatments, with brands such as Glimestar for diabetes and Manforce (Rx) for sexual health. The company's consumer healthcare products complement its prescription offerings, expanding market reach. Revenue streams come from the direct sale of branded formulations to distributors and retail chains, with no mention of external partnerships or additional services beyond pharmaceutical manufacturing and marketing. The company's therapeutic portfolio spans anti-malarial, blood-related, hormones, antineoplastic, hepatoprotective, and parenteral treatments, supported by brands like Cefakind for infections and Zenflox for respiratory issues. Sales are driven by its diverse product range covering both prescription and consumer healthcare segments, with no indication of licensing agreements or third-party collaborations. Mankind Pharma's revenue model relies solely on the marketing and distribution of its own branded pharmaceutical products within India's healthcare ecosystem. Mankind Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mankind Pharma stock

Net Debt per Share of Mankind Pharma is 151.79 INR in 2025.

Net Debt per Share of Mankind Pharma changed from -78.70 INR to 151.79 INR, representing a -292.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Mankind Pharma since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Mankind Pharma

All Key Metrics — Mankind Pharma